Patents by Inventor Isabel De Vleeschauwer

Isabel De Vleeschauwer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine protection assay
    Patent number: 9023606
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: May 5, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • Serum bactericidal assay for specific antisera
    Patent number: 8679770
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: March 25, 2014
    Assignee: Glaxo Smith Kline Biologicals S.A.
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • Vaccine Protection Assay
    Publication number: 20110165590
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Application
    Filed: March 14, 2011
    Publication date: July 7, 2011
    Inventors: Isabel DE VLEESCHAUWER, Nathalie DURANT, Jan POOLMAN, Vincent WEYNANTS
  • Vaccine protection assay
    Patent number: 7955817
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: June 7, 2011
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • Serum Bactericidal Assay for N. Meningitidis Specific Antisera
    Publication number: 20080220457
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Application
    Filed: September 5, 2005
    Publication date: September 11, 2008
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • Vaccine Protection Assay
    Publication number: 20080064057
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Application
    Filed: August 31, 2006
    Publication date: March 13, 2008
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan T. Poolman, Vincent Weynants